Top Story

FDA approves Cyramza for mCRC

April 24, 2015

The FDA today announced the approval of ramucirumab for use in combination with FOLFIRI chemotherapy for the treatment of certain patients with metastatic colorectal cancer.

The current approval of ramucirumab (Cyramza, Eli Lilly) is intended for patients with metastatic colorectal cancer (mCRC) who experienced disease progression after first-line treatment with a regimen containing bevacizumab (Avastin, Genentech), oxaliplatin and fluoropyrimidine.

NAFLD-related HCC increasing in US, expected to continue Meeting News Coverage

NAFLD-related HCC increasing in US, expected to continue

April 24, 2015
VIENNA — As non-alcoholic fatty liver disease reaches ‘epidemic’ status, its relation to hepatocellular carcinoma is also on the rise with a higher…
In the Journals

Transoral robotic surgery alone acceptable for oropharyngeal cancer

April 24, 2015
Transoral robotic surgery, or TORS, alone resulted in acceptable short- and long-term quality-of-life outcomes in well-chosen patients with oropharyngeal squamous cell…
Meeting News CoveragePerspective

Metformin may not improve survival in pancreatic cancer

April 24, 2015
PHILADELPHIA — The diabetes drug metformin was not associated with improved survival outcomes for patients with pancreatic cancer, according to retrospective study…
Meeting News Coverage

American Association for Thoracic Surgery annual meeting to highlight lung cancer, resection

April 24, 2015 will present live coverage from the American Association for Thoracic Surgery Annual Meeting that runs April 25-29 in Seattle.Coverage will…
More News Headlines »
Activity cover

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates

This activity is supported by an educational grant from Merck & Co., Inc.

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
Meeting News Coverage Video
VIDEO: Immunotherapy developments show 'real promise' in melanoma

VIDEO: Immunotherapy developments show 'real promise' in melanoma

April 16, 2015
Steven J. O’Day, MD, discusses new advancements in immunotherapies and checkpoint inhibitors — such as…
More »
High Risk AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 2 High Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »